International Clinical Trial: 68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07209865) titled '68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI' on Sept. 30.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).

Primary Sponsor: First Affiliated Hospital of Fujian Medical University

Condition: Prostate Cancer (Adenocarcinoma)

Intervention: Drug: 68Ga-P16-093

Recruitment Status: Recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: October 1, 2024

Target Sample Size: 50

Countries of Recruitment: China

To know more, visit https://clinicaltria...